Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA halts marketing of certain unapproved narcotics

Executive Summary

Nine companies received FDA warning letters March 31 for manufacturing 14 unapproved narcotic drugs including high concentrate morphine sulfate oral solutions and immediate release tablets containing morphine sulfate, hydromorphone or oxycodone. The companies cited include Boehringer Ingelheim Roxane; Cody Laboratories; Glenmark Pharmaceuticals; Lannett Company; Lehigh Valley Technologies; Mallinckrodt; Physician's Total Care; Roxane Laboratories; and Xanodyne. The warning letters were sent as part of FDA's initiative on marketed unapproved drugs (1"The Pink Sheet," June 12, 2006, p. 10)
Advertisement

Related Content

Legal News: Teva V. FDA, Pay-For-Delay, Citizen Petitions, User Fee Scheme
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions
FDA Crackdown On Unapproved Drugs Has Incentives For Voluntary Submissions

Topics

Advertisement
UsernamePublicRestriction

Register

PS050907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel